Asia-Pacific Bioinformatics Market, By Type (Knowledge Management Tools, Bioinformatics Software and Services), Sector (Medical Biotechnology, Academics, Animal Biotechnology, Agricultural Biotechnology, Environmental Biotechnology, Forensic Biotechnology and Others), Application (Genomics & Drug Development, Proteomics, Evolutionary Studies, Agricultural Studies, Veterinary Science, Metabolomics, Transcriptomics and Others), Purchase Mode (Group Purchase and Individual Purchase), Method (Genomics and Proteomics) End-User, (Research and Academic Institutes, Clinical Research Organization, Biotech and Pharmaceutical Companies, Research Laboratories, Hospital and Others) - Industry Trends and Forecast to 2029.
Asia-Pacific Bioinformatics Market Analysis and Insights
The rise in demand for advanced computational bioinformatics, transcriptomics, protemics tools in Molecular Biology research followed by increase in requirements for integrated bioinformatics in proteomic, genomic, & clinical diagnostics, and numerous bioinformatics organizations providing outsourcing resources are expected to drive the market growth.
However, the lack of skilled and trained expertise to use the computational tools is expected to restrain the segment growth.
The increased partnership with market players for use of bioinformatics software is expected to drive the market growth. Data Bridge Market Research analyzes that the Asia-Pacific bioinformatics market will grow at a CAGR of 17.8% during the forecast period of 2022 to 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Type (Knowledge Management Tools, Bioinformatics Software and Services), Sector (Medical Biotechnology, Academics, Animal Biotechnology, Agricultural Biotechnology, Environmental Biotechnology, Forensic Biotechnology and Others), Application (Genomics & Drug Development, Proteomics, Evolutionary Studies, Agricultural Studies, Veterinary Science, Metabolomics, Transcriptomics and Others), Purchase Mode (Group Purchase and Individual Purchase), Method (Genomics and Proteomics) End-User, (Research and Academic Institutes, Clinical Research Organization, Biotech and Pharmaceutical Companies, Research Laboratories, Hospital and Others)
|
|
Countries Covered
|
China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., QIAGEN,SOPHiA GENETICS., BGI, Eurofins Scientific, Waters Corporation, Partek Incorporated, Dassault Système, Bayer AG, PerkinElmer Inc., Quest Diagnostics Incorporated., AstridBio Technologies Inc., BioBam, Strand Life Science, GenoFAB, Inc.
|
Market Definition
Bioinformatics combines computer programming, big data, and Molecular Biology, which enables scientists to understand and identify patterns in biological data. It is particularly useful in studying genomes and DNA sequencing, as it allows scientists to organize large amounts of data.
From genetics to toxicology to mycology and radiobiology, there are scores of branches of Biology to specialize in. And out of the many, Bioinformatics is one of the intriguing fields which enables you to identify, evaluate, store, and retrieve biological information. Being an interdisciplinary field of study, it incorporates various applications of Computer Science, Statistics, and Biology to develop software applications for understanding biological data like DNA sequencing, protein analysis, evolutionary genetics, etc.
In the coming future, important decisions related to bioinformatics on drug discovery will be made by individuals who not only understand the biology but can also use the bioinformatics tools and the knowledge they release to develop hypotheses and identify quality targets
Asia-Pacific Bioinformatics Market Dynamics
Drivers
- Increasing Public-Private Sector Funding For Bioinformatics
In order to improve the workflow for bioinformatics, the federal agencies and the public and private agencies are providing funds to carry out bioinformatics projects and to scientists for research. It is important to approach possible funders with a clear proposal and strategy of what is to be achieved in terms of bioinformatics capacity building in the institution as well as the intended outputs and outcomes.
For instance;
- In April 2022, Illumina, Inc. initiated the six-month cyclic funding in the San Francisco Bay Area or Cambridge, the U.K., for bioinformatics start-up
- In October 2020, SOPHiA GENETICS raised USD 110 million for financing for the next stage of its expansion, with a focus on supporting the growing clinical and biopharma demand for Data-Driven Medicine worldwide
The funding by the public and private sectors would result in the rise of bioinformatics startups and projects. The funding would expedite and expand the institute's technical infrastructure. This includes setting up new data storage solutions and scaling existing data resources. The funding will also be used to provide secure, shared analysis platforms for major research collaborations. Hence the public-private sector funding for bioinformatics is expected to drive market growth.
- Use of Bioinformatics in Personalized Medicine
The growth curve for bioinformatics market clinical applications is following an upward trend as established applications are gaining momentum and new ones are finding a foothold. Product development in the past years has helped the market size to grow. This also shows the support of the regulatory agency for allowing these products in the market.
For instance-
- In June 2021, Agilent Technologies, Inc. released a new exome design called Sure Select Human All Exon V8 that offers specific content and coverage of protein-coding areas from Refuses, CCDS, and GENCODE. Additionally, it includes exons that are challenging to capture and the TERT promoter, which are neglected by competing exomes
The product development in recent years has shown the potential of these technologies, and the companies working in this market are trying to get the more advanced product in the market, which is expected to create a lucrative opportunity for market growth in the forecast period.
Opportunities
- Strategic Initiatives by Market Players
Bioinformatics delivers purposeful biological information, as it is a part of life science dealing with the comprehension and planning of genomes. A genome is the complex arrangement of genetic sets present in a cell or a whole living being. Personalized medicine is a combinatorial way to deal with individual-specific health care. The patient-specific medication development advanced through bioinformatics tools.
For instance-
- In December 2020, Quest Diagnostics Incorporated invested in Structural Bioinformatics, A Leader in Computational Proteomics and Structural Pharmacogenomics. The investment resulted in the joint development of a series of database modules of the novel, structurally variant proteins and market these products directly to the pharmaceutical and biotechnology industry for use in the development of personalized medicine
- In 2019, BGI announced that Flow Pharma had selected BGI (A subsidiary of BGI Group) for developing the use of NSG in Drug Development
Hence the growing prevalence of chronic disease and increased drug-resistance issues in traditional medication have generated the demand for increasing bioinformatics in drug development. This is expected to be one of the major factors expected to drive the market growth in the forecast period.
- Advancement in bioinformatics technology
The dimensions and cost of bioinformatics platforms and instruments are decreasing, allowing easier uptake by public health laboratories. Although currently, bioinformatics requires highly specialized equipment and substantially skilled staff to analyze the data, it is unlikely that the bioinformatics revolution has finished. With rising technology, up-gradation of instruments and techniques is also needed. Moreover, the bioinformatics market has a vast potential to upgrade various applications, and there are high chances of advancing bioinformatics techniques in the forecast period.
- E-Health.
E-health equipment and technologies. Processing of information in e-health. Services and applications for telemedicine and e-health. Image processing in medicine. Medical imaging approaches using video. Combining traditional treatment with electronic health
With time, technological advancements put pressure on manufacturers and researchers to change instruments and techniques to cope with modern problems. Thus bioinformatics has the potential to get updated with time and is expected to create opportunities for the new player and existing players to bring a new product to the market.
Restraints/Challenges
- Challenges to Implementing Bioinformatics Technology in The Clinical Labs
Bioinformatics technologies can perform massively complicated biological data analysis. This capacity simultaneously facilitates the computational tools for the organization and analysis of biological data, which helps improve diagnostic screening. The application of these powerful technologies in a clinical laboratory poses a challenge because of the data's scope, quantity, and medico-technical consequences.
Various challenges of implementing next-generation sequencing in the clinical laboratory are as follows-
- One of the first areas where problems can creep in is often the most overlooked: "sample quality". Although platforms are often tested and compared using highly curated samples (such as the reference material from the Genome in a Bottle Consortium), real-world samples often present much more of a challenge and hence act as a challenge for the rise in demand.
- High turn-around time is also a major challenge for the instruments working in this market.
- Library Preparation
The above challenge poses complications for adopting bioinformatics in the clinical laboratory, due to which fewer clinical laboratories are adopting this technology. Thus, the challenges of implementing bioinformatics technology in the clinical lab are expected to hamper the market growth.
- Cyber Security Concerns in Bioinformatics
Era software is known to contain vulnerabilities caused by imperfect code and misconfiguration. NGS-related software used to operate sequencing and laboratory equipment or carry out bioinformatics analyzes is no exception. Software vulnerabilities are exploited to gain unauthorized access to computer systems or networks, leak data, crash or otherwise disrupt various services.
However, the increasing computerization of DNA technology and biotechnology raises new bio-cyber security concerns. Vulnerabilities typically associated with traditional computer systems -- like the processing of untrusted input, side-channel leaks, poor authentication, falsified data, and vulnerabilities in cyber-physical systems -- now exist in biotechnology. The emerging bio-cyber security threats have threatened the DNA-Information Systems in bioinformatics.
For instance;
- In 2020, The REvil or Sodinokibi ransomware group will take the credit for hacking and stealing 1 Terabyte (TB) of data from 10x Genomics which is for COVID-19 research
- In 2018, Genomics England shifted genetic blueprint data for its 100,000 Genomes Project after being targeted by cyber-attacks from foreign parties. This allows the breach of data and can lead to misuse of individual genome
COVID-19 Impact on the Asia-Pacific Bioinformatics Market
During the pandemic, the Asia-Pacific bioinformatics sector is one that focuses on using a combination of biology and information technology. Biological data is analyzed and transformed at the heart of the industry using IT techniques. Bioinformatics has always had huge potential in providing essential support to many areas of scientific research. The bioinformatics industry in Asia-Pacific has experienced rapid growth opportunities before the pandemic owing to efficient bioinformatics tools, which can handle large volumes of biological data.
The tools that bioinformatics can provide allow scientists to get to grips with larger data sets and to mine and analyze them to discover crucial information that could lead to key discoveries. In recent years, genetics and genomes have been the primary focus of Bioinformatics, including comparative genomics, DNA microarrays, and functional genomics. The COVID-19 pandemic has seen widespread application of genomic approaches to understand the epidemiology and evolution of SARS-CoV-2 virus. The accelerated efforts to sequence SARS-CoV-2 genomes picked up pace following the initial genome sequencing of the virus from a patient in Wuhan, the epicenter for the pandemic with substantial increases at the emergence of variants of the SARS-CoV-2 virus.
Recent Development
- In March 2022, Thermo Fisher Scientific Inc launched the CE-IVD Marked Next-Generation Sequencing (NGS) Instrument for Use in Clinical Labs. The CE-IVD Marked Next-Generation Sequencing Instrument is used to perform diagnostic testing and clinical research on a single instrument. The launch of the instrument resulted in the addition of a new product in the product range and the distribution of the NGS instrument, which is expected to increase the product revenue.
Asia-Pacific Bioinformatics Market Scope
Asia-Pacific bioinformatics market is segmented on the basis of six segments: type, sector, application, purchase mode, genomics, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Knowledge Management Tools
- Bioinformatics Software
- Services
On the basis of type, the Asia-Pacific bioinformatics market is segmented into knowledge management tools, bioinformatics software, and services.
Sector
- Medical biotechnology
- Academics
- Animal Biotechnology
- Agricultural biotechnology
- Environmental Biotechnology
- Forensic biotechnology
- Others
On the basis of sector, the Asia-Pacific bioinformatics market is segmented into medical biotechnology, academics, animal biotechnology, agricultural biotechnology, environmental biotechnology, forensic biotechnology, and others.
Application
- Genomics and Drug Development
- Proteomics
- Evolutionary Studies
- Agricultural Studies
- Veterinary Science
- Metabolomics
- Transcriptomics
- Others
On the basis of application, the Asia-Pacific bioinformatics market is segmented into genomics and drug development, proteomics, evolutionary studies, agricultural studies, veterinary science, metabolomics, transcriptomics, and others.
Purchase Mode
- Group Purchase
- Individual Purchase
On the basis of purchase mode, the Asia-Pacific bioinformatics market is segmented into group purchases and individual purchases.
Method
- Genomics
- Proteomics
On the basis of method, the Asia-Pacific bioinformatics market is segmented into genomics and proteomics.
End User
- Research and Academic Institutes
- Clinical Research Organization
- Biotech and Pharmaceutical Companies
- Research Laboratories
- Hospital
- Others
On the basis of end-user, the Asia-Pacific bioinformatics market is segmented into research and academic institutes, clinical research organizations, biotech and pharmaceutical companies, research laboratories, hospitals, and others.
Asia-Pacific Bioinformatics Market Regional Analysis/Insights
Asia-Pacific bioinformatics market is analyzed, and regions provide market size insights and trends, type, sector, application, purchase mode, genomics, and end-user, as referenced above.
The countries covered in the Asia-Pacific bioinformatics market report are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific.
China is expected to dominate the market due to a rise in the incidence of rise in research and development activity and due to integrated bioinformatics requirements in proteomic, genomic, & clinical diagnostics, combined with the surging demand for advanced computational tools in biological research.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of brands and their challenges faced due to large or scarce competition from local and domestic brands impact sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Bioinformatics Market Share Analysis
Asia-Pacific bioinformatics market competitive landscape provides details on the competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, the Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the Asia-Pacific Bioinformatics market.
Some of the major players operating in the Asia-Pacific bioinformatics market are Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., QIAGEN, SOPHiA GENETICS., BGI, Eurofins Scientific, Waters Corporation, Partek Incorporated, Dassault Système, Bayer AG, PerkinElmer Inc., Quest Diagnostics Incorporated., AstridBio Technologies Inc., BioBam, Strand Life Science, GenoFAB, Inc.
SKU-